Stop Hep B @ Birth

Stop Hep B @ Birth: Community-Oriented Care Model for the Prevention of Mother-To-Child Transmission of Hepatitis B in Peri-Urban Yangon

Single arm, prospective open-label study of a care model consisting of two components: Component I aims to achieve high coverage of interventions to prevent maternal-to-child transmission of hepatitis B virus: antenatal tenofovir, and timely newborn administration of hepatitis B birth dose vaccine and hepatitis B immune globulin; Component II aims to achieve high coverage of screening, vaccination, and anti-viral therapy for HBV among household members of women with chronic HBV infection.

Study Overview

• Status: Recruiting
• Conditions: Hepatitis B
• Intervention / Treatment: Drug: Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG); Drug: Regular Myanmar treatment

Detailed Description

An estimated 248 million people worldwide are chronically infected with hepatitis B virus (HBV); and 75% of them live in Asia. Mother-to-child transmission (MTCT) accounts for the majority of chronic hepatitis B infections in Southeast Asia. Elimination of MTCT of HBV is theoretically possible with a comprehensive suite of interventions that includes birth dose vaccination, hepatitis B immune globulin, and antenatal antiviral therapy (e.g., tenofovir). However, the ideal gestational age to initiate antenatal tenofovir remains undefined; and evidence is lacking for implementation strategies capable of providing cost-effective, equitable access to a comprehensive suite of interventions to prevent MTCT of HBV in low-resource settings.

Component I: Prevention of Vertical Transmission Pregnant women living in the study area will be identified and screened for hepatitis B by a network of antenatal care (ANC) providers and existing community outreach workers; HBsAg positive patients will be invited to participate in the study. Consenting participants will provide serum samples to assess eligibility for anti-viral therapy: creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, HCV, HIV. Pregnant women eligible for antiviral therapy according to WHO criteria, or who have viral load (VL) >200,000 IU/mL, will be treated with tenofovir starting at 20 weeks gestation through 4 weeks postpartum. Hospital-based delivery will be encouraged. All newborns, including those delivered at home, will receive the HBV birth dose vaccine within 24 hours of delivery, and newborns of women on tenofovir treatment will also receive Hepatitis B Immunoglobulin within 24 hours after delivery. Children will be linked to routine immunization services in Myanmar to complete their HBV vaccination series (HBV is co-formulated in a pentavalent vaccine). Maternal VL will be measured at delivery; infants will be tested for hepatitis B infection at 24-28 weeks postpartum.

Component II -- Household Screening and Treatment The household members of HBsAg positive pregnant women who consent to participate in the study will be screened for HBV-related immune status and chronic HBV infection. Non-immune individuals (HBsAb/Ag negative) will be vaccinated; HBsAg positive household members will be assessed for treatment eligibility and initiated on anti-viral therapy according to World Helath Organization guidelines. Eligible household members will also be screened every six months for hepatocellular carcinoma (HCC) by liver ulatrasound and alpha-fetoprotein levels

Qualitative Study:

In-depth interviews with approximately 30 HBsAg-positive women, 30 HBVsAg-negative women, and 20 household members of study participants will be conducted to assess barriers and facilitators related to HBV testing and treatment. Approximately 15 key-informant interviews with healthcare providers and community leaders will also be conducted. Sample size will depend on data saturation and will be adjusted based on results of data analysis during the study.

• Study Type: Interventional
• Enrollment (Anticipated): 110
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Khin Pyone Kyi, MD; Phone Number: +95 9 250 022 398; Email: pmcthbv2018kpk@gmail.com
• Study Contact Backup: Name: Eindra Htoo, MD; Phone Number: +95 9 975 477 478; Email: eindrahtoo@cpintl.org

Study Locations

• Myanmar
  • Yangon, Myanmar
    • Recruiting
    • BK Kee Clinic
    • Contact: Hnin Nandar Htut; Email: nandar@bkkeefoundation.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Pregnant women >= 18 years of age
• Gestational age =<34 weeks
• Test positive for HBsAg
• Live in study site area in South Dagon and Dagon Seikkan Townships, Yangon Region
• Give informed consent to participate in the study
• Newborns and household members of pregnant women enrolled in the study according to previous inclusion criteria

Exclusion Criteria:

• Alanine aminotransferase (ALT) levels >300 IU/L

For qualitative study:

Inclusion criteria

• Key informants (e.g., healthcare providers and community leaders in the study area) OR
• HBsAg+ women and their household members in the study area
• HBsAg- women and their household members in the stud area
• Give informed consent to participate in the study
• History of renal dysfunction
• CrCL < 50mL/min
• ALT>5 times the upper limit of normal (ULN)
• Evidence of decompensated cirrhosis (e.g., jaundice, ascites, history of upper gastrointestinal bleeding/esophageal varices, and hepatic encephalopathy)
• Any concomitant condition or treatment that, in view of the clinical site investigator, would contraindicate participation or satisfactory follow-up in the study HIV positive status unless 1) they are currently on additional ART therapy, or 2) their viral load is demonstrated to be <50 copies. Women who are newly diagnosed with HIV and referred to start a TDF-based regimen may be considered eligible once they have started the TDF-based regimen.
• Concurrent participation in any other clinical trial without written agreement of the study team
• Does not intend to deliver within catchment area, and/or intends to migrate before newborn follow-up is complete

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Tenofovir Disoproxil Fumerate; Pregnant women (>=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible). Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.

Drug: Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG); Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV; Other Names: Viread; Drug: Regular Myanmar treatment; Treated according to normal Myanmar processes for HBV positive patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vaccine within 24 hours	Proportion of newborns of HBsAg positive mothers receiving HBV vaccine within 24 hours of birth	Within 24 hours of birth
Effective treatment of pregnant women	Proportions of pregnant women with chronic HBV (HBsAg positive) who are (a) linked to care (attend BK Kee Clinic for assessment of treatment eligibility); (b) complete TDF eligibility testing; (c) initiate tenofovir treatment (TDF, among those eligible); (d) adhere to TDF treatment until delivery and (e) continue treatment until 4 weeks post-partum o Low/medium/high high medication adherence are defined, respectively, as ≤6, 6-7 or 8 points on the Morisky Medication Adherence Scale (MMAS-8)	During pregnancy (until delivery) of each woman, average of 9 months
Household contact screening	Proportions of adult household contacts who (a) are screened for chronic HBV infection and immunity (HBsAg/Ab); (b) are linked to care (among HBsAg positive) or vaccinated (if HBsAb negative); (c) complete appropriate testing for hepatocellular carcinoma (HCC) screening, (d) eligible for TDF treatment; (e) initiate chronic HBV treatment with TDF	Upon identification of participating women, until the end of the project, average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total screening of mothers	Proportion of pregnant women in the target population who are: screened for HBsAg (denominator estimated from population census counts and crude birth rate); HBsAg positive (chronic HBV prevalence among women attending ANC)	During pregnancy (until delivery) of each woman, average of 9 months
Antenatal care for HBV positive pregnant mothers	Proportions of pregnant women with chronic HBV who: attend their first antenatal care (ANC) visit prior to 20, 24, 28 and 32 weeks gestation; are eligible for TDF (HBV VL >200,00 IU/mL or WHO criteria); are HBeAg positive; deliver at home	During pregnancy (until delivery) of each woman, average of 9 months
Vaccination of HBV negative pregnant mothers	Proportion of women who tested negative for HBsAg and HBsAb at baseline who complete the HBV vaccination schedule	During pregnancy (until delivery) of each woman, average of 9 months
Treatment of high viral load pregnant mothers	Among women who had VL>200,000 IU/mL at baseline and were eligible for TDF treatment: the proportion that achieve viral suppression (HBV DNA <200,000 IU/mL) at delivery; the proportion who are HBeAg positive; proportion with HBV flare 4 months postpartum (ALT >300 IU/L)	At delivery; during antenatal care testing; at 4 months postpartum, throughout the project, average of 12 months
Viral suppression	Associations of maternal viral suppression (VL <200,000 at delivery and: baseline HBV VL, duration of exposure to TDF, and TDF adherence	At delivery, throughout the project (one off)
Mother-to-child transmission	Proportion of infants born to HBsAg positive mothers who; complete the HBV vaccination series within the recommended intervals; are HBsAg positive or with measurable HBV VL at 28 weeks postpartum (rate of mother-to-child transmission of HBV)	At 28 weeks postpartum, throughout the project (one off)
Household screening	Among household members screened for HBsAg and HBsAb: o Prevalence of chronic infection (% HBsAg positive); and immune status (% HBsAb positive and HBsAg negative)	At household screening, throughout the project (one off)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Completed vaccination courses	Proportion of infants of HBsAg positive mothers who complete HBV vaccination prior to study termination, before and after coronavirus- and coup- related delays in public vaccination program	Before age 1, average of 1 year
Proportion of pregnant women with HBsAg identified by surveillance team members	Proportion of pregnant women with HBsAg identified by surveillance team members	During pregnancy, average of 9 months
Timeliness of pregnancy surveillance	Among pregnant women identified by surveillance team members: Proportion who are linked to care and screened for HBsAg; Proportions identified prior to gestational age of 20, 24, 28 and 32 weeks	During pregnancy, average of 9 months
Equity of intervention	Distributions of select outcomes according to age, sex and axes of social disadvantage: household wealth; educational attainment; occupation; and ethnic/religious affiliation	During pregnancy and in first year after delivery, average of 16 months

Collaborators and Investigators

• Sponsor: Myanmar Liver Foundation
• Investigators: Principal Investigator: Khin Phone Kyi, MD, Myanmar Liver Foundation; Principal Investigator: Adam K Richards, MD, University of California, Los Angeles

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2018
• Primary Completion (Anticipated): December 30, 2021
• Study Completion (Anticipated): June 30, 2023

Study Registration Dates

• First Submitted: January 19, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 10, 2021

Study Record Updates

• Last Update Posted (Actual): August 10, 2021
• Last Update Submitted That Met QC Criteria: August 3, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Hepatitis B; Hepatitis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Immunologic Factors; Tenofovir; Antibodies; Immunoglobulins; Immunoglobulins, Intravenous; gamma-Globulins; Rho(D) Immune Globulin
• Other Study ID Numbers: HBV2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: The investigators are currently developing an individual participant data (IPD) sharing plan.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No